Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Becton Dickinson and Co Please stand by. We're about to begin. Good day everyone. Welcome to today's conference call to discuss BD's first quarter fiscal 2025 earnings and BD's announcement of its ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton, Dickinson and Company (BDX ... The choice corresponds with BD's 2025 plan, which aims to maximize capital allocation, hasten expansion, and follows a thorough portfolio review starting ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson BDX1.16%increase ... Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest ...

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...